academic article

• Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial..  The Lancet. Oncology.  13:100-110. 2012
• Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial..  The Lancet. Oncology.  13:89-99. 2012
• Risk factors for incident condyloma in a multinational cohort of men: the HIM study..  The Journal of infectious diseases.  205:789-793. 2012
• Human papillomavirus (HPV) 6, 11, 16, and 18 seroprevalence is associated with sexual practice and age: results from the multinational HPV Infection in Men Study (HIM Study)..  Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.  20:990-1002. 2011
• Incidence and human papillomavirus (HPV) type distribution of genital warts in a multinational cohort of men: the HPV in men study..  The Journal of infectious diseases.  204:1886-1892. 2011
• Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial..  Lancet.  369:2161-2170. 2007